Schedule by Topic


 

*Pulmonary Hypertension (PH)

Below is a list of all sessions for which PH is listed as the Primary Audience. For a comprehensive list of all sessions that may be of interest to professionals in the field of pulmonary hypertension, visit our online Program Viewer.
 

Tuesday, April 21, 2020

 

8:15 AM – 5:40 PM

 

Wednesday, April 22, 2020

 

4:15 PM – 6:00 PM

Primary Audience: PH
Secondary Audience: CTEPH, HF/HTX, PEDS

Session Summary: Patients with PH are at higher risk for adverse outcomes in elective and non-elective surgery. This session reviews pre-operative risk assessment and the evaluation and management of patients and the intra-operative and post-operative consideration to minimize adverse outcomes. The role of peri-operative MCS is explored. The session will include a debate on the role of PAC monitoring. This symposium heralds the ISHLT expert consensus document currently under development. A panel discussion with all speakers will conclude this session.

Chairs: Marc Simon, MD and Teresa De Marco, MD
 
4:15 PM The Calm Before the Storm: Preoperative Evaluation and Management
Dana McGlothlin, MD, Kaiser Permanente, San Francisco, CA, USA
4:30 PM The Raging Storm: Intraoperative Considerations and Management
Karen M. McRae, MD, Toronto General Hospital, Toronto, ON, Canada
4:45 PM The Aftermath: Postoperative Considerations and Management
Oksana A. Shlobin, MD, Inova Fairfax Hospital, Falls Church, VA, USA
5:00 PM Tread Carefully: Patient with Eisenmenger's Undergoing Surgery
Erika Berman-Rosenzweig, MD, Columbia University Hospital, New York, NY, USA
5:15 PM DEBATE: PAC Monitoring is Essential in the Management of the High Risk PAH Patient Undergoing Surgery (PRO)
Celine Dewachter, MD, Erasme Hospital, Brussels, Belgium
5:30 PM DEBATE: PAC Monitoring is Essential in the Management of the High Risk PAH Patient Undergoing Surgery (CON)
Stuart Hastings, MBBS, The Alfred Hospital, Melbourne, Australia
5:45 PM Panel Discussion
 

Thursday, April 23, 2020

 

7:00 AM – 8:00 AM

Primary Audience: PH
Secondary Audiences: CTEPH

Session Summary: This session will review the new topics in the literature regarding portopulmonary hypertension. It will review the pathogenesis of portopulmonary hypertension and other forms of PAH related to liver disease, it will review the emerging treatment options for patients with portopulmonary hypertension, and will include a great debate on role of liver transplantation in treatment of portopulmonary hypertension.

Chairs: Nicholas A. Kolaitis, MD and Daniel H. Kim, MD
 
7:00 AM Case Presentation: RVSP"itis": Patient with Newly Diagnosed Portopulmonary Hypertension
Sophia Airhart, MD, University of Arizona, Tucson, AZ, USA
7:05 AM There Goes the Neighborhood: Updates in Pathogenesis, Epidemiology and Treatment of Portopulmonary Hypertension
Olivier Sitbon, MD, Hopital Universitaire de Bicêtre, Paris Sud, France
7:20 AM DEBATE: Liver Transplantation is a Treatment For Portopulmonary Hypertension (PRO)
Thenappan Thenappan, MD, University of Minnesota, Minneapolis, MN, USA
7:35 AM DEBATE: Liver Transplantation is a Treatment For Portopulmonary Hypertension (CON)
Kelly Chin, MD, UT Southwestern Medical Center, Dallas, TX, USA
7:50 AM Panel Discussion
 

Friday, April 24, 2020

 

8:15 AM – 10:00 AM

Primary Audience: PH
Secondary Audience: BSTR, CTEPH, LF/LTX, PEDS

Session Summary: In collaboration with the Pulmonary Vascular Research Institute (PVRI), the ISHLT is pleased to offer this joint symposium. The management of PAH has considerably evolved in the past years; however, the development of disease-modifying therapies faces challenges witnessed by a high number of negative Phase II trials. Do we make the right choice of agents? Should we change our RCT paradigm? How do we measure success and how does this translate in real-life management? These are some key questions the symposium will try to answer with world-leading experts who will discuss how the future will look like.

Chairs: Paul Corris, MB FRCP and Trevor Williams, MD
 
8:15 AM Journey to the Center of the Cell: New Pathways and Beyond
Sebastien Bonnet, PhD, FAHA, Pulmonary Hypertension Research Group, Quebec, QC, Canada
8:40 AM Intolerable Cruelty or Why Phase II Trials Failed
Olivier Sitbon, MD, Hopital Universitaire de Bicêtre, Paris Sud, France
9:05 AM Facing the Void: How Do We Define Success in PAH?
Jean-Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium
9:25 AM The Full Monty: Tools and Tricks for a Better Management
Raymond L. Benza, MD, Allegheny General Hospital, Pittsburgh, PA, USA
9:50 AM Panel Discussion
 

10:30 AM – 12:15 PM

Primary Audience: PH
Secondary Audience: CTEPH, HF/HTX, LF/LTX, MCS, PEDS

Session Summary: This session will focus on the role of mechanical circulatory support (ventricular assist devices, impeller devices, extracorporeal membranous oxygenation devices, etc) in the management of patients with advanced pulmonary hypertension with severe and complex heart failure physiology.

Chairs: Arun Jose, MD and Maria G. Crespo-Leiro, MD
 
2:00 PM Knowing When to Bail: Timing and Candidacy in MCS for End Stage Pulmonary Hypertension
Manreet Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA, USA
2:15 PM Q & A
2:20 PM Tickle Me ECMO: What is the Best Configuration to Support the Failing Right Ventricle?
Sonja Bartolome, MD, UT Southwestern, Dallas, TX, USA
2:35 PM Q & A
2:40 PM DEBATE: ECMO Should Be Routine Perioperatively for PAH Patients Undergoing Transplant (PRO)
David McGiffin, MD, Alfred Institute, Melbourne, Australia
2:55 PM DEBATE: ECMO Should Be Routine Perioperatively for PAH Patients Undergoing Transplant (CON)
Christopher King, MD, Inova Fairfax Hospital, Falls Church, VA, USA
3:10 PM Debate Rebuttal (PRO)
David McGiffin, MD, Alfred Institute, Melbourne, Australia
3:15 PM Debate Rebuttal (CON)
Christopher King, MD, Inova Fairfax Hospital, Falls Church, VA, USA
3:20 PM Future of MCS in Management of RV Failure: Will it be Destination Therapy for Patients with PAH?
Olaf Mercier, MD, Paris-Sud University, Paris, France
3:35 PM Q & A
 

Saturday, April 25, 2020

 

7:00 AM – 8:00 AM

Primary Audience: PH
Secondary Audience: HF/HTX, LF/LTX, NHSAH, PEDS, PHARM

Session Summary: Advanced cardiopulmonary disease (both the disease and treatment) has a devastating effect of quality of life (QoL). Palliative care support as a treatment option is very much underutilized in patients with end stage heart and lung disease both before and after transplantation. This session will focus on how to integrate palliative care and improve QoL both before and after transplantation. A panel discussion with all speakers will conclude this session.

Chairs: Sasha Storaasli, MD and Sandeep Sahay, MD
 
7:00 AM CASE PRESENTATION: End-Stage Cardiopulmonary Disease
Sandeep Sahay, MD, Houston Methodist Hospital, Houston, TX, USA
7:05 AM A Breath of Fresh Air: Management of Dyspnea in End Stage Heart/Lung Disease
Rebecca Colman, MD, University of Toronto, Toronto, ON, Canada
7:20 AM This Could Go a Couple of Ways: Understanding How Preoperative Expectations of Quality of Life After Transplant Measure Up with Actual Experience
Meghan Aversa, MD, New York Presbyterian at Columbia University, New York, NY, USA
7:35 AM A Shared Reality: Seeing Through the Lens by All Providers, Starting Early
Eric Nolley, MD, MS, Johns Hopkins, Baltimore, MD, USA
7:50 AM Panel Discussion


*This schedule at a glance is updated each Friday to reflect any changes in information, including room names, session times, speaker information